Frankfurt:MOR

I-Mab Biopharma and MorphoSys Announce China IND Submission of TJ202/MOR202

SHANGHAI, Aug. 7, 2018 /PRNewswire/ -- On August 8, 2018 Beijing time I-Mab Biopharma ("I-Mab"), aShanghai-based biotech company focused on innovative biologics in oncology and autoimmune disease, and German biopharma company MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; NASDAQ: MOR) an...

2018-08-08 09:01 1090

Week's Top Stories